| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1166101 | Analytica Chimica Acta | 2012 | 6 Pages |
A novel immunoassay for the determination of tumor markers in human serum was established by combining a time-resolved fluoroimmunoassay (TRFIA) and immunomagnetic separation. Based on a sandwich-type immunoassay format, analytes in samples were captured by magnetic beads coated with one monoclonal antibody and “sandwiched” by another monoclonal antibody labeled with europium chelates. The immunocomplex was separated and washed by exposure to a magnetic field and treatment with enhancement solution; fluorescence was then measured according to the number of europium ions dissociated. Levels of the model analyte, carcinoembryonic antigen (CEA), were determined in a linear range (1–1000 ng mL−1) with a limit of detection of 0.5 ng mL−1 under optimal conditions. The reproducibility, recovery, and specificity of the immunoassay were demonstrated to be acceptable. To evaluate this novel assay for clinical applications, 239 serum samples were evaluated. Compared with the conventional TRFIA and chemiluminescence immunoassay (CLIA), the correlation coefficients of the developed immunoassay were 0.985 and 0.975, respectively. These results showed good correlation and confirmed that our method is feasible and could be used for the clinical determination of CEA (or other tumor antigens) in human serum.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Magnetic beads was used as the solid phase for TRFIA. ► The linearity range was broadened greatly compared with conventional TRFIA method. ► The analysis time was significantly shorter compared with conventional TRFIA method. ► This method could be developed for practical clinical detections of tumor-associated antigens.
